This site is intended for UK healthcare professionals

 
Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications Ltd with an arm’s length sponsorship towards the development of the British Journal of Cardiology masterclasses.
novartis-logo-transparent

Optimising care in cardiovascular disease patients with chronic kidney disease

25 February 2025
Available for 1 CPD point(s)

Masterclass

Dr Jemima Scott and Professor Chris Gale discuss the bidirectional relationship between heart and kidney disease, and how treatment strategies can be developed that address both cardiovascular and renal risk in these vulnerable patients.
Learning objectives
  • To understand the prevalence of coexisting cardiovascular and kidney disease
  • To provide guidance on detecting cardiovascular or kidney disease, and when to refer such patients for specialist care
  • To describe the similarities and differences between guidelines on the management of cardiovascular and kidney disease
  • To discuss the role of pharmacological treatment options in reducing both cardiovascular and renal risk
Speakers

Dr Jemima Scott NIHR Doctoral Research Fellow and Specialty Trainee in renal medicine, University of Bristol and North Bristol NHS Trust
Professor Chris Gale Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References:

  1. Entresto (sacubitril/valsartan) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15041/smpc (accessed February 2025)
  2. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3666/smpc (accessed February 2025)
  3. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2025)
  4. NICE. Chronic kidney dissease: Scenario: Management of chronic kidney disease. September 2024. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/ (accessed February 2025)
  5. Saeed D et al. Cureus. 2023;15:e51362
  6. Song JH et al. BMC Nephrology. 2023;24:289

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.